These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35315387)

  • 1. Substance use disorders during the COVID-19 pandemic: looking for new innovative approaches.
    Piersanti V; Consalvo F; Marinelli E
    Acta Biomed; 2022 Mar; 93(1):e2022081. PubMed ID: 35315387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learnt from alcoholism and substance use disorders (SUDs) during the COVID-19 pandemic in India.
    Saleem SM; Shoib S; Dey R; Gundroo HM; Zaidi I
    J Prev Med Hyg; 2021 Dec; 62(4):E859-E863. PubMed ID: 35603247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID 19-impact on substance use treatment utilization and provision in South Africa.
    Harker N; Johnson K; Erasmus J; Myers B
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):15. PubMed ID: 35241095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substance abuse in times of COVID-19 pandemic: a "perfect storm" for substance use disorder and mental health?
    Pirani F; Del Rio A
    Clin Ter; 2021 Nov; 172(6):525-526. PubMed ID: 34821345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persons with Substance Abuse Disorders and Other Addictions: Coping with the COVID-19 Pandemic.
    Fabelo-Roche JR; Iglesias-Moré S; Gómez-García AM
    MEDICC Rev; 2021 Apr; 23(2):55. PubMed ID: 33974609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of COVID-19 lockdown on individuals under treatment for substance use disorders: Risk factors for adverse mental health outcomes.
    Blithikioti C; Nuño L; Paniello B; Gual A; Miquel L
    J Psychiatr Res; 2021 Jul; 139():47-53. PubMed ID: 34029833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City.
    Hurley EA; Piña K; Cegielski V; Noel-MacDonnell JR; Miller MK
    J Subst Abuse Treat; 2021 Oct; 129():108378. PubMed ID: 34080549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic.
    López-Pelayo H; Aubin HJ; Drummond C; Dom G; Pascual F; Rehm J; Saitz R; Scafato E; Gual A
    BMC Med; 2020 Jul; 18(1):241. PubMed ID: 32731868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and correlates of alcohol and other substance use disorders in young adulthood: A population-based study.
    Latvala A; Tuulio-Henriksson A; Perälä J; Saarni SI; Aalto-Setälä T; Aro H; Korhonen T; Koskinen S; Lönnqvist J; Kaprio J; Suvisaari J
    BMC Psychiatry; 2009 Nov; 9():73. PubMed ID: 19925643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Global Pandemic and Substance Use Disorder: Healthcare Professionals' Viewpoints on the Merging of Two Crises.
    Shreffler J; Shreffler M; Murfree JR; Huecker M
    Subst Use Misuse; 2021; 56(10):1476-1482. PubMed ID: 34130597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Converging Impact of the Ongoing Conflict and COVID-19 Pandemic on Mental Health and Substance Use Disorders in Ukraine.
    Patel SS; Sukhovii O; Zvinchuk O; Neylan JH; Erickson TB
    J Emerg Manag; 2021; 19(9):63-68. PubMed ID: 35281482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research on substance use disorders during the COVID-19 pandemic.
    Volkow ND; Blanco C
    J Subst Abuse Treat; 2021 Oct; 129():108385. PubMed ID: 34080553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review.
    Mallet J; Dubertret C; Le Strat Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110070. PubMed ID: 32800868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "How can I hug someone now [over the phone]?": Impacts of COVID-19 on peer recovery specialists and clients in substance use treatment.
    Anvari MS; Seitz-Brown CJ; Spencer J; Mulheron M; Abdelwahab S; Borba CPC; Magidson JF; Felton JW
    J Subst Abuse Treat; 2021 Dec; 131():108649. PubMed ID: 34716038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaboration in a time of crisis: Adapting a telementoring ECHO for addiction leaders during COVID-19.
    Englander H; Patten A; Gregg J
    Subst Abus; 2022; 43(1):547-550. PubMed ID: 34520678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
    Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
    Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: Substance-specific and substance-aggregated correlates.
    McCabe SE; West BT; Strobbe S; Boyd CJ
    J Subst Abuse Treat; 2018 Oct; 93():38-48. PubMed ID: 30126540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of addiction treatment among U.S. adults with history of incarceration and substance use disorders.
    Tsai J; Gu X
    Addict Sci Clin Pract; 2019 Mar; 14(1):9. PubMed ID: 30836991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance use disorders increase the odds of subsequent mood disorders.
    Kenneson A; Funderburk JS; Maisto SA
    Drug Alcohol Depend; 2013 Dec; 133(2):338-43. PubMed ID: 23906994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts of COVID-19 on residential treatment programs for substance use disorder.
    Pagano A; Hosakote S; Kapiteni K; Straus ER; Wong J; Guydish JR
    J Subst Abuse Treat; 2021 Apr; 123():108255. PubMed ID: 33375986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.